RxDoctor Payments Data

John McGath, MD

Otolaryngology · Duncan, OKNPI 1699721977

Payments from drug & device makers

$418in general payments, 2019–2025

Across 8 payments — averaging $52.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$257
  • Regeneron Healthcare Solutions, Inc.$76
  • Greer Laboratories, Inc.$32
  • GSK$20
  • Sanofi$18
  • Optinose US, Inc.$15

What the payments were for

  • Food & beverage$36186%
  • Education$5814%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker2$257
Regeneron Healthcare Solutions, Inc.2$76
Greer Laboratories, Inc.1$32
GSK1$20
Sanofi1$18
Optinose US, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$418 in reported general payments places this provider in the 30th percentile of 109 otolaryngology providers in Oklahoma.

See all otolaryngology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$140,005
Medicare patients
426
Services billed
2,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dexlansoprazole DrDexlansoprazole16$4,811
Breo ElliptaFluticasone/Vilanterol11$4,409
Montelukast Sodium209$2,282
Ipratropium Bromide83$1,940
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth15$1,922
Epinephrine11$1,813
Armour ThyroidThyroid,pork24$1,457
Levothyroxine Sodium44$859
Clonidine12$661
Pantoprazole Sodium36$616
Fluticasone Propionate37$467
Ofloxacin22$373
Omeprazole33$369
CefuroximeCefuroxime Axetil27$296
Azithromycin30$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$20$4,40911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 109 otolaryngology providers in Oklahoma.

Other otolaryngology in Duncan

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →